Navigation Links
NuView Life Sciences and Thomas Jefferson University Sign Agreement for Exclusive Development and Commercialization Rights to Novel Prostate Cancer Diagnostic
Date:3/26/2013

Park City, UT (PRWEB) March 26, 2013

NuView Life Sciences (NLS), a privately-held company developing next generation imaging and in vitro diagnostic biomarkers with the ability to identify and locate disease at the earliest stages of development, today announced it has entered into an agreement with Thomas Jefferson University for exclusive development and commercialization rights to a novel urine screen for the early detection of Prostate and Bladder Cancer.

“We are excited to add this technology into the NuView Portfolio. This in vitro diagnostic is an excellent complement to our diagnostic imaging biomarkers in development,” stated Brian Dowd, Ph.D., Vice President of Clinical and Scientific Affairs at NLS. “Early and accurate detection of Prostate and Bladder Cancer should result in a significant reduction of invasive biopsy procedures and increase the probability for successful treatment outcomes in patients.”

This novel in vitro diagnostic (IVD) detects minute quantities of cancer cells shed into the urinary tract by measuring the expression of the vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1 (VPAC1) receptor. To date, the technology has displayed impressive sensitivity and specificity for the identification of Prostate and Bladder Cancer in human urine samples.

Previous work by Mathew Thakur, Ph.D., academic collaborator, Professor Radiology and Director of Radiopharmaceutical Research and Molecular Imaging at Thomas Jefferson University (TJU), Philadelphia, has shown Prostate Cancer cells express the oncogene product VPAC1 in high density on their cell surface. This occurs at a very early stage in oncogenic transformation, well before cell morphology alterations for histologic confirmation, and even well before the elevation of Prostate Specific Antigen (PSA). NuView is also developing NLS-VPAC1, a positron emission tomography (PET)-based imaging agent that measures VPAC1 expression levels for identification and localization of malignant Breast and Prostate tumors.

There remains a large unmet medical need for the accurate and early detection of Prostate and Bladder Cancer. Prostate cancer is the second leading cause of cancer death in American men and over 72,000 men and women are estimated to be diagnosed with Bladder Cancer in the U.S. in 2013. Mortality from Prostate and Bladder Cancer strongly correlates with the stage of disease upon diagnosis. Therefore, the ability to detect early-stage cancer before clinical presentation would have a dramatic effect upon patient outcomes.

Currently, routine screening of the general public for bladder cancer is not recommended by any major professional organization. This is due to lack of a sensitive and specific test that will detect bladder cancer in individual not presenting clinical symptoms of disease. Current screening for Prostate Cancer by digital rectal examination (DRE) and Prostate Specific Antigen (PSA) tests results in low cancer predictive ability and increases the number of referrals for invasive biopsy.

About NuView Life Sciences

NuView Life Sciences is a privately held company whose mission is the development and commercialization of a new generation of molecular imaging diagnostic agents and disease-specific biomarkers. We are developing a vertically integrated, radiopharmaceutical manufacturing, and distribution organization to address current supply problems in the marketplace and facilitate development of our product pipeline.

For more information, please visit http://www.nuviewinfo.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10545119.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
2. Digital Science & SciBite Join Forces to Harness Big Data for Life Sciences
3. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
4. RoviSys Partners with POMS MES to Expand Life Sciences Capabilities
5. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
6. A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
7. Life Sciences Technology Conference and Career Fair on March 26th in Raleigh, NC
8. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
9. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
10. Lockheed Martin to Continue Providing Life Sciences Support to NASA
11. Nasseo Wins CONNECT Life Sciences Capital Competition and Joins CONNECT Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... separable adhesive layers, as issued by the U.S. Patent & Trademark Office (USPTO). ... to combining electronics and health monitoring. This invention will be critical to the ...
(Date:3/29/2017)...  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions ... results for the fourth quarter and full year ... a pivotal year for us with our first ... agreements, major reimbursement progress with Medicare, positive medical ... addition we cleared our 2 nd generation ...
(Date:3/29/2017)... year,s petition to the White House signed by 120,000 ... generate awareness on the importance of new organic medicines and nutritional ... place. ... this month Health Advance (OTC PINK: HADV ), ... announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... announce that Nerium International Mexico has been approved as an active member of ... achieve satisfaction and protection among distributers and consumers in relationship marketing. This professional ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):